Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cotsiranib,Lixadesiran
Therapeutic Area : Dermatology
Study Phase : Phase I
Recipient : Sirnaomics
Deal Size : Undisclosed
Deal Type : Partnership
Sirnaomics Partners with Gore Range to Establish JV Sagesse Bio for RNAi Therapeutics
Details : The partnership with Sagesse will rapidly advance Sirnaomics' lead product STP705 (Pixofisiran/Lixadesiran) that targets TGF-ß1/COX-2. It is being evaluated to address body contouring & fat reduction.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
July 31, 2024
Lead Product(s) : Cotsiranib,Lixadesiran
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Recipient : Sirnaomics
Deal Size : Undisclosed
Deal Type : Partnership